• GT Biopharma shareholders approved increasing authorized common shares from 25,000,000 to 250,000,000 at a special meeting on November 11, 2026.
• They also authorized common stock issuance upon conversion of Series M 10% Convertible Preferred Stock and exercise of Warrants.
• A charter amendment eliminating references to obsolete preferred stock series passed; both charter amendments were authorized for implementation by November 11, 2027.
• Shareholders also approved adjournment if needed to establish a quorum or solicit additional proxies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051221), on November 12, 2026, and is solely responsible for the information contained therein.